Jasper Therapeutics/$JSPR
About Jasper Therapeutics
Ticker
Industry
Employees
JSPR Metrics
$100M
-
-$4.67
2.20
-
Price and volume
Market cap
$100M
Beta
2.2
52-week high
$31.01
52-week low
$6.30
Average daily volume
547K
Financial strength
Current ratio
7.609
Quick ratio
7.445
Long term debt to equity
1.207
Total debt to equity
2.473
Management effectiveness
Return on assets (TTM)
-40.92%
Return on equity (TTM)
-71.46%
Valuation
Price to book
1.2
Price to tangible book (TTM)
1.2
Price to free cash flow (TTM)
-1.551
Growth
Earnings per share change (TTM)
-34.28%
3-year earnings per share growth (CAGR)
-65.68%
What the Analysts think about JSPR
Analyst Ratings
JSPR Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
JSPR Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
JSPR News
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma
Jasper Therapeutics to Participate at Upcoming Investor Conferences
FAQs
What’s the current market cap for Jasper Therapeutics stock?
What is the P/E ratio for Jasper Therapeutics stock?
Does Jasper Therapeutics stock pay dividends?
No, Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Jasper Therapeutics dividend payment date?
Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Jasper Therapeutics?
Jasper Therapeutics (JSPR) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.